Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Sea Otter who wrote (3026)	4/16/2000 1:23:00 AM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

Sea Otter, While I think you hit the nail on the head, I'd like to take it one step further. If we treat Pancreatic Cancer patients and have any kind of success, it will be more than just statistically promising. I believe putting any Pancreatic Patients into remission would put the drug into the fastest Fast Track Phase 3 Trial the FDA has ever run, and I do believe they'd take over the trial. I don't know if they'd separate the other cancers or if they'd accelerate the complete trial. I, like you, believe the results with all cancers could be so outstanding that the FDA will recognize the drugs capability and rush it through to approval. Pancreatic Cancer would be the icing on the cake as it is almost always fatal, and the best modern medicine has been able to do is extend life expectancy a few months. I believe the reason they waited to dose the first Pancreatic Cancer Patient was because they wanted to get the dosage high enough that they could do some good, and where repeated dosing could lead to remission. They knew the Colon Cancer Patient could last long enough for dosage levels that could be effective, but Pancreatic and non small cell Lung Cancer Patients couldn't wait for the higher level doses. If I've counted the weeks correctly, last week they should have received their second dose, and three new patients should be started at higher dosage levels. Gary